Additionally, adriamycin (Dox) induces the upregulation of breast cancer resistance protein (ABCG2) and P-GP in endothelial cells, leading to the increased resistance of breast cancer cells to sunitinib [14,96,97]. This evidence concerns the gene ABCG2 and breast carcinoma.